Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine - Summary - MDSpire

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • By

  • Spyros Chalkias

  • Antionette Pragalos

  • Adebayo Akinsola

  • Gary Berman

  • Madhavi Ampajwala

  • Jay Meyer

  • Lorraine Schoch

  • Wen Zhou

  • Yamuna D Paila

  • Weiping Deng

  • Jing Feng

  • Elizabeth de Windt

  • Darin Edwards

  • Jacqueline Miller

  • Rituparna Das

  • January 10, 2025

  • 0 min

Share

Objective:

To evaluate the safety and immunogenicity of the mRNA-1283 vaccine and its formulations compared to the mRNA-1273 vaccine.

Key Findings:
  • All dose levels of mRNA-1283 vaccines were well tolerated.
  • mRNA-1283 elicited higher neutralizing antibody responses than mRNA-1273.
  • Antibody responses remained detectable for a year postvaccination.
Interpretation:

mRNA-1283 demonstrated improved safety and immunogenicity compared to the original mRNA-1273 vaccine.

Limitations:
  • Study participants were limited to those previously vaccinated with mRNA-1273.
  • Long-term efficacy and safety beyond one year remain to be evaluated.
Conclusion:

mRNA-1283 is a promising candidate for COVID-19 vaccination, showing better immunogenicity and safety profiles.

Original Source(s)

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine

  • by Spyros Chalkias, Antionette Pragalos, Adebayo Akinsola, Gary Berman, Madhavi Ampajwala, Jay Meyer, Lorraine Schoch, Wen Zhou, Yamuna D Paila, Weiping Deng, Jing Feng, Elizabeth de Windt, Darin Edwards, Jacqueline Miller, Rituparna Das

  • January 10, 2025

Related Content

Explainable machine learning-based mortality risk stratification for older adults with COVID-19: pinpointing core immunological biomarkers and revealing dose-threshold effects

Effectiveness of Telemedicine vs Face-to-Face Consultation in Fighting COVID-19: Retrospective Cohort Study of Adult Patients With COVID-19 in a Primary Care Setting

Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions